GSK plc directors purchased ordinary shares and ADS on September 18, 2026, including 1,500 ordinary shares at £18.8110 and 1,734 ADS at $49.8534. The transaction details give investors named participants, instruments, prices and trading venues for the reported director share purchases.
Key Highlights
- Sir Jonathan Symonds purchased 1,500 GSK ordinary shares at £18.8110 each.
- Charles Bancroft purchased 1,734 GSK American Depositary Shares at $49.8534 each.
- The reported purchases took place on September 18, 2026, on the London Stock Exchange and New York Stock Exchange.
GSK plc (NYSE: GSK) is a Pharmaceuticals: Major company. On September 18, 2026, Sir Jonathan Symonds bought 1,500 ordinary shares at £18.8110 each, while Charles Bancroft purchased 1,734 American Depositary Shares at $49.8534 each. The purchases took place on the London Stock Exchange and New York Stock Exchange, respectively.
GSK Share Purchases Span London and New York
The London transaction covered ordinary shares, while the New York transactions involved American Depositary Shares. Elizabeth (Liz) McKee Anderson, Dr Anne Beal, Dr Hal Dietz, Dr Jeannie Lee and Dr Vishal Sikka also purchased ADS on the New York Stock Exchange. Roy Jackobs purchased ordinary shares on the London Stock Exchange. Each transaction was recorded separately as a single transaction. Symonds is identified as Non-Executive Chair.
FAQs
Q: What price did GSK director Sir Jonathan Symonds pay for ordinary shares?
A: Sir Jonathan Symonds paid £18.8110 for each GSK ordinary share. The transaction involved 1,500 ordinary shares on September 18, 2026.
Q: Which GSK securities were purchased on the New York Stock Exchange?
A: Directors purchased GSK American Depositary Shares on the New York Stock Exchange. Charles Bancroft’s transaction involved 1,734 ADS at $49.8534 each.
Q: Who signed GSK’s transaction report on September 22, 2026?
A: Victoria Whyte signed the report as an authorised signatory for and on behalf of GSK plc. The filing was dated September 22, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.